RSS Atom • ISSN 1472-4683 • Subscribe • About
Lipodystrophy and metabolic complications
- No association between bone mineral density and lipodystrophy in women receiving antiretroviral therapy Antiretrovirals - Conference reports - Lipodystrophy and metabolic complications - Women's health - Intl Workshop on HIV and Women 1st 2011 - 1 February 2011
- Intestinal microflora and low grade metabolic inflammation Conference reports - Lipodystrophy and metabolic complications - 1 February 2011
- Complex connections between bone and fat metabolism Conference reports - Lipodystrophy and metabolic complications - PK and drug interactions - 1 February 2011
- UK studies on bone health: increased fracture rates reported in HIV-positive people Conference reports - Lipodystrophy and metabolic complications - Side effects - HIV 10 Glasgow 2010 - 1 December 2010
- 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, 4–6 November 2010, London Conference reports - Lipodystrophy and metabolic complications - Conference index - Lipodystrophy Workshop (IWADRW) 12 London 2010 - 1 December 2010
- Bio-Alcamid associated with unacceptable complication risk: no longer recommended as a treatment for facial lipoatrophy Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 12 London 2010 - 1 December 2010
- Age raises fracture risk more in HIV-positive people Conference reports - Lipodystrophy and metabolic complications - HIV and Ageing Baltimore 2010 - 1 December 2010
- FDA approves tesamorelin for reduction of central fat accumulation Lipodystrophy and metabolic complications - Side effects - 1 December 2010
- Tesamorelin for reduction of central fat accumulation: regulatory decision delayed in the US Lipodystrophy and metabolic complications - Side effects - 1 October 2010
- 75% HIV-positive children have insufficient levels of Vitamin D Conference reports - Lipodystrophy and metabolic complications - Paediatric care - Side effects - BHIVA/BASHH 2nd Manchester 2010 - 1 June 2010
- High rates of osteopenia and osteoporosis: importance of DEXA monitoring Conference reports - Lipodystrophy and metabolic complications - Side effects - BHIVA/BASHH 2nd Manchester 2010 - 1 June 2010
- ACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naïve patients Antiretrovirals - Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 17 (Retrovirus) 2010 - 2 April 2010
- Clinical benefits of stopping smoking: CVD and CHD risk returns to that of ‘previous smoker’ in HIV-positive people within three years Cancer and HIV - Conference reports - Lipodystrophy and metabolic complications - CROI 17 (Retrovirus) 2010 - 2 April 2010
- Vitamin D deficiencies in HIV management Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 17 (Retrovirus) 2010 - 2 April 2010
- Central fat accumulation remains a significant problem in patients starting HAART after 2005 with higher incidence in women compared to men Conference reports - Lipodystrophy and metabolic complications - Side effects - Women's health - EACS 12 Cologne 2009 - 21 February 2010
- Gender and race differences in lipodystrophy symptoms Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 11 Philadelphia 2009 - 31 December 2009
- Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 11 Philadelphia 2009 - 31 December 2009
- Raltegravir body composition study: 48-week DEXA results Conference reports - Lipodystrophy and metabolic complications - Side effects - ICAAC 49th San Fransisco 2009 - 31 December 2009
- Lipid and metabolic changes with ARV combinations Conference reports - Lipodystrophy and metabolic complications - Side effects - IAS 5 Cape Town 2009 - 5 October 2009
- Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy Conference reports - Lipodystrophy and metabolic complications - Side effects - ICAAC 48th Washington 2008 - 26 December 2008
- Statin use in HIV-positive patients Conference reports - Lipodystrophy and metabolic complications - Side effects - ICAAC 48th Washington 2008 - 26 December 2008
- New-fill used to treat lipoatropy in feet Conference reports - Lipodystrophy and metabolic complications - Side effects - BHIVA 14th Belfast 2008 - 12 June 2008
- Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results Conference reports - Lipodystrophy and metabolic complications - Side effects - EACS 11 Madrid 2007 - 2 December 2007
- Growth hormone release factor (TH9507) reduces central fat adiposity Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 14 (Retrovirus) 2007 - 4 April 2007
- d4T associated with significantly increased risk of type-2 diabetes mellitus Conference reports - Lipodystrophy and metabolic complications - Side effects - HIV 8 Glasgow 2006 - 6 December 2006
- Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia Conference reports - Lipodystrophy and metabolic complications - Side effects - HIV 8 Glasgow 2006 - 6 December 2006
- The role of the metabolic syndrome in HIV Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 8 San Francisco 2006 - 15 October 2006
- Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 8 San Francisco 2006 - 9 October 2006
- Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 8 San Francisco 2006 - 9 October 2006
- Interventions for the management of lipodystrophy and metabolic complications Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 13 (Retrovirus) 2006 - 25 March 2006
- Uridine supplement reverses thymidine-induced lipoatrophy Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005
- Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005
- Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005
- Niacin has beneficial effect on lipids but no reduction in abdominal fat Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005
- Gluteal implants used to replace lost buttock fat Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005
- Omega-3 supplement effective to reduce triglycerides Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 12 (Retrovirus) 2005 - 18 April 2005
- Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 12 (Retrovirus) 2005 - 18 April 2005
- Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 12 (Retrovirus) 2005 - 18 April 2005
- Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 6 Washington 2004 - 31 January 2005
- Potential for uridine to treat mitochondrial toxicity: still only in vitro data Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 6 Washington 2004 - 31 January 2005
- rHGH reduces central fat accumulation in adolescent lipodystrophy Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 6 Washington 2004 - 31 January 2005
- Pravastatin improves lipid profiles but not endothelial function Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 6 Washington 2004 - 31 January 2005
- Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 6 Washington 2004 - 31 January 2005
- Improvement of lipids following switch to tenofovir Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 6 Washington 2004 - 31 January 2005
- Restorative treatments for HIV-associated lipoatrophy Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 6 Washington 2004 - 31 January 2005
- Vancouver researchers urge caution with combinations of lipid drugs Lipodystrophy and metabolic complications - Side effects - 6 November 2004
- Phase II results show ThGRF could be safe, effective treatment for lipodystrophy, says company Lipodystrophy and metabolic complications - Side effects - 2 June 2004
- Reversibility of lipoatrophy in HIV patients 2 years after switching from a thymidine analogue to abacavir Lipodystrophy and metabolic complications - Side effects - 2 June 2004
- Diabetes and HIV and HCV; aging/HIV and diabetes Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 11 (Retrovirus) 2004 - 2 May 2004
- FDA panel recommends approval of New-Fill Lipodystrophy and metabolic complications - Side effects - 2 May 2004
- Lipodystrophy regresses in three patients switched to atazanavir Lipodystrophy and metabolic complications - Side effects - 2 May 2004
- Low-dose rHGH maintains reductions in abdominal fat for 60 weeks Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 11 (Retrovirus) 2004 - 3 April 2004
- Rosiglitazone shows no benefit for lipoatrophy Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 11 (Retrovirus) 2004 - 2 April 2004
- Importance of dietary management in treating lipid disorders: soy diets may offer comparable effect as statins Lipodystrophy and metabolic complications - Side effects - 3 February 2004
- Human histology and persistence of various injectable filler substances for soft tissue augmentation Lipodystrophy and metabolic complications - 3 February 2004
- Lower doses of d4T produce similar efficacy and reduced side effects Conference reports - Lipodystrophy and metabolic complications - Side effects - EACS 9 Warsaw 2003 - 1 December 2003
- Polylactic acid (New-Fill) repairs facial wasting and improves quality of life Lipodystrophy and metabolic complications - 1 December 2003
- Canadian study shows increased interventional cardiovascular procedures associated with HAART Lipodystrophy and metabolic complications - 1 November 2003
- New guidelines for the evaluation and management of dyslipidaemia in HIV patients on HAART Lipodystrophy and metabolic complications - 1 October 2003
- Treatments for lipoatrophy. Are there improvements? Are they noticeable? Lipodystrophy and metabolic complications - 1 October 2003
- Rosiglitazone significantly increases triglyceride and cholesterol levels and does not improve HAART-associated lipoatrophy Lipodystrophy and metabolic complications - 1 October 2003
- US approves and Europe rejects Serostim (recombinant growth hormone) for treatment of HIV-related wasting Lipodystrophy and metabolic complications - 1 October 2003
- 5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris Conference reports - Lipodystrophy and metabolic complications - Conference index - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- Underlying mechanisms: adipocytes and cytokines Basic science and immunology - Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- More mitochondrial DNA depletion Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- IMT and cardiovascular risk Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- Reduced bone mineral density in HIV-positive women Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- Rosiglitazone with insulin resistance Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- Additional benefits of exercise with metformin Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir Antiretrovirals - Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- Facial fat loss – measuring and treatment Conference reports - Lipodystrophy and metabolic complications - Treatment access - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- Uridine treatment for mitochondrial toxicity Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- Breast enlargement in men and testosterone treatment Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- Treatment interruption: a real choice Conference reports - Lipodystrophy and metabolic complications - Treatment strategies - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003
- HIV and heart disease: D:A:D prevalence rates show importance of accessing CVD risk in HIV patients Lipodystrophy and metabolic complications - 1 July 2003
- HAART increases body fat at first; both d4T and AZT lead to subsequent fat loss Lipodystrophy and metabolic complications - 1 July 2003
- Lipoatrophy improved by switching from d4T to abacavir Lipodystrophy and metabolic complications - 1 July 2003
- Metabolic abnormalities in protease inhibitor-treated and protease naïve children Lipodystrophy and metabolic complications - Paediatric care - 1 July 2003
- High levels of gout may be linked to HAART Conference reports - Lipodystrophy and metabolic complications - Side effects - BHIVA 9th Manchester 2003 - 1 June 2003
- Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women Lipodystrophy and metabolic complications - 1 June 2003
- Statins and fibrates both relatively effective for PI-induced hyperlipidemia Lipodystrophy and metabolic complications - 1 May 2003
- Pioglitazone subjectively improves body shape abnormalities Lipodystrophy and metabolic complications - 1 May 2003
- Conference has strong emphasis on women Cancer and HIV - Conference reports - Lipodystrophy and metabolic complications - Women's health - CROI 10 (Retrovirus) 2003 - 1 April 2003
- Approaches to treatment of lipodystrophy Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 10 (Retrovirus) 2003 - 1 April 2003
- Surgery for buffalo hump shows variable results depending on method Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 10 (Retrovirus) 2003 - 1 April 2003
- Other studies – nucleosides and switching to abacavir; importance of lipoatrophy and buffalo hump Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 10 (Retrovirus) 2003 - 1 April 2003
- HAART to HEART: cardiovascular risk in HIV Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 10 (Retrovirus) 2003 - 1 April 2003
- Alendronate, vitamin D and calcium are safe and effective treatment for HIV-associated bone loss Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 10 (Retrovirus) 2003 - 1 April 2003
- Bone loss and fat loss are closely related in HIV patients on HAART Conference reports - Lipodystrophy and metabolic complications - Side effects - CROI 10 (Retrovirus) 2003 - 1 April 2003
- Reduced testosterone levels in HIV-positive women Lipodystrophy and metabolic complications - Other news - Women's health - 1 April 2003
- 30-year study links vitamin A to risk of fracture in humans Lipodystrophy and metabolic complications - 1 March 2003
- Bone turnover elevated in HIV-positive patients and linked to duration of HAART Lipodystrophy and metabolic complications - 1 March 2003
- Protease inhibitors and cardiovascular outcomes in patients with HIV-1 Lipodystrophy and metabolic complications - Side effects - 1 March 2003
- HIV protease inhibitors promote atherosclerosis independent of dyslipidemia Lipodystrophy and metabolic complications - Side effects - 1 March 2003
- HAART-associated hyperlipidaemia linked to low risk for cardiovascular disease (CVD) Lipodystrophy and metabolic complications - 1 March 2003
- Patient on human growth hormone develops tumours with growth hormone receptors Lipodystrophy and metabolic complications - 1 March 2003
- Review of trials shows testosterone increases lean body mass, and is most effective when given intramuscularly Lipodystrophy and metabolic complications - 1 March 2003
- An overview of the conference Antiretrovirals - Conference reports - Lipodystrophy and metabolic complications - HIV 6 Glasgow 2003 - 1 February 2003
- Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients Antiretrovirals - Conference reports - Lipodystrophy and metabolic complications - Side effects - HIV 6 Glasgow 2003 - 1 February 2003